NTRC Publications on Oncolines, SynergyFinder:

References to Oncolines, SynergyFinder, Mechanistic Cell Biology:

  • Cordo et al. (2019) Phospho-Proteomic Profiling of T-Cell Acute Lymphoblastic Leukemia Identifies Specific Kinase Activation Signatures That Can Predict Response to Targeted Therapy, ASH Annual Meeting 2019, Orlando, December 07-10, Poster Abstract #4649. (Affiliation: Princess Máxima Center for Pediatric Oncology)
  • Conlon et al. (2019) Pre-clinical assessment of neratinib sensitivity and biomarkers of response, AACR-NCI-EORTC Conference Molecular Targets and Cancer Therapeutics, Boston, October 26-30, Abstract A046. (Affiliations: Dublin City University, Puma Biotechnology Inc.)
  • Borsari et al. (2019) Preclinical Development of PQR514, a Highly Potent PI3K Inhibitor Bearing a Difluoromethyl−Pyrimidine Moiety, ACS Medicinal Chemistry Letters, 10:1473-1479. (Affilitations: University of Basel, PIQUR Therapeutics AG)
    https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.9b00333
  • Rageot et al. (2019) (S)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable Dual Inhibitor of Class I PI3K and mTOR Kinase, Journal of Medicinal Chemistry, 62 (13):6241-6261. (Affiliations: University of Basel, PIQUR Therapeutics AG)
    https://doi.org/10.1021/acs.jmedchem.9b00525
  • Grünewald et al. (2019) Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models, International Journal of Cancer, 145 (5): 346-1357. (Affiliation: Bayer AG)
    https://doi.org/10.1002/ijc.32224
  • Gentile et al. (2018) A Novel Interaction Between the TLR7 and a Colchicine Derivative Revealed Through a Computational and Experimental Study, Pharmaceuticals, 11 (1):22. (Affiliation: University of Alberta)
    https://doi.org/10.3390/ph11010022
  • Bohnacker et al. (2017) Deconvolution of Buparlisib’s mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention, Nature Communications, 8:14683. (Affiliation: University of Basel)
    https://www.nature.com/articles/ncomms14683
  • Libouban et al. (2017) Stable aneuploid tumors cells are more sensitive to TTK inhibition than chromosomally unstable cell lines, Oncotarget, 8 (24):38309–38325. (Affiliations: Netherlands Cancer Institute, NTRC)
    https://doi.org/10.18632/oncotarget.16213
  • Canté-Barrett et al. (2016) MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia, Leukemia, 30:1832-1843. (Affiliation: Erasmus MC)
    https://www.nature.com/articles/leu201683
  • Maia et al. (2015) Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model, Annals of Oncology, 26 (10):2180-2192. (Affiliation: Netherlands Cancer Institute)
    https://doi.org/10.1093/annonc/mdv293
back to home